Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-cash Items (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Non-cash Items data on record, last reported at $7.5 million in Q4 2025.

  • For Q4 2025, Non-cash Items fell 22.78% year-over-year to $7.5 million; the TTM value through Dec 2025 reached $7.5 million, down 22.78%, while the annual FY2025 figure was $7.5 million, 22.78% down from the prior year.
  • Non-cash Items reached $7.5 million in Q4 2025 per SNDX's latest filing, down from $9.7 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $88.0 million in Q4 2022 and bottomed at $83000.0 in Q1 2022.
  • Average Non-cash Items over 5 years is $21.8 million, with a median of $3.9 million recorded in 2022.
  • Peak YoY movement for Non-cash Items: surged 103.21% in 2021, then crashed 99.74% in 2022.
  • A 5-year view of Non-cash Items shows it stood at $68.6 million in 2021, then grew by 28.29% to $88.0 million in 2022, then plummeted by 37.41% to $55.1 million in 2023, then plummeted by 82.31% to $9.7 million in 2024, then decreased by 22.78% to $7.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $7.5 million in Q4 2025, $9.7 million in Q4 2024, and $55.1 million in Q4 2023.